The most pressing questions in ITP involve finding a cure and developing treatments safe for use during pregnancy.
David Kuter, MD, DPhil
Advertisement
David Kuter, MD, DPhil, is director of clinical hematology at Massachusetts General Hospital and professor of medicine at Harvard Medical School.
Articles by David Kuter, MD, DPhil
Rilzabrutinib (Wayrilz; Sanofi), a BTK inhibitor, targets immune-mediated platelet destruction in immune thrombocytopenia (ITP) and has demonstrated a favorable safety profile.
Rilzabrutinib (Wayrilz; Sanofi) may improve immune thrombocytopenia (ITP) outcomes, enable early intervention, and enhance patient quality of life.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
CDC Reduces US Childhood Immunization Schedule From 17 to 11 Diseases
2
GLP-1s More Effective at Preventing Colorectal Cancer Than Aspirin
3
Nimbus Therapeutics, Eli Lilly Partner to Develop Novel Oral Metabolic Drug
4
Telemedicine Utilization and Preventive Services Among a Rural Population
5
